Repeat Biopsy: Mining for Patients

Pressed on how to rescue patients labelled “HER2-zero,” the panel argues that time, fixation quality, and sheer persistence convert more zeros to low/ultra-low than any new drug ever will. Calling the pathologist to re-examine old blocks, or scheduling a fresh core at times when nothing usable remains regularly will bring to light the faint signal needed to unlock T-DXd. Dana-Farber data even has shown that the probability of detecting HER2 staining climbs with every successive biopsy, underscoring why archival tissue is oncology’s buried treasure.